- Home
- PLUS vs SUPN Comparison
PLUS vs SUPN Comparison
Compare PLUS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUS
- SUPN
- Stock Information
- Founded
- PLUS 1990
- SUPN 2005
- Country
- PLUS United States
- SUPN United States
- Employees
- PLUS N/A
- SUPN N/A
- Industry
- PLUS Retail: Computer Software & Peripheral Equipment
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- PLUS Technology
- SUPN Health Care
- Exchange
- PLUS Nasdaq
- SUPN Nasdaq
- Market Cap
- PLUS 1.7B
- SUPN 1.7B
- IPO Year
- PLUS 1996
- SUPN 2012
- Fundamental
- Price
- PLUS $61.30
- SUPN $31.68
- Analyst Decision
- PLUS Hold
- SUPN Hold
- Analyst Count
- PLUS 1
- SUPN 2
- Target Price
- PLUS $90.00
- SUPN $36.00
- AVG Volume (30 Days)
- PLUS 271.4K
- SUPN 646.8K
- Earning Date
- PLUS 05-21-2025
- SUPN 05-07-2025
- Dividend Yield
- PLUS N/A
- SUPN N/A
- EPS Growth
- PLUS N/A
- SUPN 6500.00
- EPS
- PLUS 3.91
- SUPN 1.32
- Revenue
- PLUS $2,125,136,000.00
- SUPN $661,817,000.00
- Revenue This Year
- PLUS N/A
- SUPN N/A
- Revenue Next Year
- PLUS $5.24
- SUPN $9.32
- P/E Ratio
- PLUS $15.69
- SUPN $24.81
- Revenue Growth
- PLUS N/A
- SUPN 8.94
- 52 Week Low
- PLUS $60.11
- SUPN $25.53
- 52 Week High
- PLUS $106.98
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- PLUS 35.88
- SUPN 40.55
- Support Level
- PLUS $60.11
- SUPN $31.74
- Resistance Level
- PLUS $66.03
- SUPN $32.87
- Average True Range (ATR)
- PLUS 2.03
- SUPN 0.93
- MACD
- PLUS 0.01
- SUPN 0.20
- Stochastic Oscillator
- PLUS 19.19
- SUPN 28.24
About PLUS ePlus inc.
ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.